Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Liss

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Cancers|November 13, 2025
Propensity Score-Matched Analysis of Neoadjuvant vs. Adjuvant Therapy in Renal Cell CarcinomaCesare Saitta, Giacomo Musso, Giuseppe Garofano, et al.
Proteomics. Clinical Applications|July 3, 2020
Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype DeterminationJoseph J Otto, Vanessa L Correll, Hampus A Engstroem, et al.
European Urology Oncology|July 11, 2025
Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort StudyNikita Sushentsev, Irene G Li, George Xu, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter AnalysisMargaret F Meagher, Natalie Birouty, Giacomo Musso, et al.
Journal of Translational Medicine|May 30, 2020
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancerStephen T Ryan, Jing Zhang, Danielle N Burner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 1, 2026
BPI26-018: Integrated Specialty Prostate Cancer Care: Outcomes From a Collaborative Clinic Model at UC San Diego Moores Cancer CenterShwena Dhar, Archana Ajmeri, Shelly Kane, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
BPI26-018: Integrated Specialty Prostate Cancer Care: Outcomes From a Collaborative Clinic Model at UC San Diego Moores Cancer CenterShwena Dhar, Archana Ajmeri, Shelly Kane, et al.
Urology Practice|May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS CohortAdrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Nutrition and Cancer|November 7, 2022
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance StudyJeannette M Schenk, Menghan Liu, Marian L Neuhouser, et al.
Prostate Cancer and Prostatic Diseases|January 22, 2019
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)Lisa F Newcomb, Yingye Zheng, Anna V Faino, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Cancers|November 13, 2025
Propensity Score-Matched Analysis of Neoadjuvant vs. Adjuvant Therapy in Renal Cell CarcinomaCesare Saitta, Giacomo Musso, Giuseppe Garofano, et al.
Proteomics. Clinical Applications|July 3, 2020
Targeted Mass Spectrometry of a Clinically Relevant PSA Variant from Post-DRE Urines for Quantitation and Genotype DeterminationJoseph J Otto, Vanessa L Correll, Hampus A Engstroem, et al.
European Urology Oncology|July 11, 2025
Predicting Active Surveillance Failure for Patients with Prostate Cancer in the Magnetic Resonance Imaging Era: A Multicentre Transatlantic Cohort StudyNikita Sushentsev, Irene G Li, George Xu, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Impact of Elevated C-Reactive Protein on Survival Outcomes of Patients with Small Renal Masses: A Retrospective Multicenter AnalysisMargaret F Meagher, Natalie Birouty, Giacomo Musso, et al.
Journal of Translational Medicine|May 30, 2020
Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancerStephen T Ryan, Jing Zhang, Danielle N Burner, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 1, 2026
BPI26-018: Integrated Specialty Prostate Cancer Care: Outcomes From a Collaborative Clinic Model at UC San Diego Moores Cancer CenterShwena Dhar, Archana Ajmeri, Shelly Kane, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 29, 2026
BPI26-018: Integrated Specialty Prostate Cancer Care: Outcomes From a Collaborative Clinic Model at UC San Diego Moores Cancer CenterShwena Dhar, Archana Ajmeri, Shelly Kane, et al.
Urology Practice|May 5, 2023
Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS CohortAdrian J Waisman Malaret, Peter Chang, Lisa Newcomb, et al.
Nutrition and Cancer|November 7, 2022
Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance StudyJeannette M Schenk, Menghan Liu, Marian L Neuhouser, et al.
Prostate Cancer and Prostatic Diseases|January 22, 2019
Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)Lisa F Newcomb, Yingye Zheng, Anna V Faino, et al.
Pageof 8